ClinicalTrials.gg
CompletedNCT07290855Updated Dec 18, 2025

A Study to Evaluate the Safety and Efficacy of Icatibant in Patients With Bradykinin Induced Angioedema

A Phase 4 interventional study of Icatibant Injection (Icanticure®) in Bradykinin-mediated Angioedema and Hereditary Angioedema (HAE), sponsored by Nang Kuang Pharmaceutical Co., Ltd.. Completed at 1 site in Taiwan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2025-12-18.

Sponsored by Nang Kuang Pharmaceutical Co., Ltd. · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Sep 2024, registered Mar 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
5
Allocation
Not applicable
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies testing icatibant in Angioedemas, Hereditary — none open to participants now, none under way, none of them phase 3. icatibant · Angioedemas, Hereditary.

Enrollment
9th of 10
5 · median 26
Started
2024
the only one that year
Phase 4
2 of 10
none open now
Registered
10th of 10
by date
Lead sponsor
1 of 10
Nang Kuang Pharmaceutical Co., Ltd.

Among the 10 studies testing icatibant in Angioedemas, Hereditary, this one is the 9th largest by enrollment, is the only one that started in 2024, is one of 2 in phase 4, and was the 10th registered.

Angioedemas, Hereditary

171 studies on the registry are indexed under Angioedemas, Hereditary; 24 are open to participants now.

Browse Angioedemas, Hereditary studies →

Open to participants now

None of the 10 studies testing icatibant in Angioedemas, Hereditary is open now. The open studies under Angioedemas, Hereditary, anywhere →

About icatibant

icatibant: first FDA approval 2011 (FIRAZYR), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 13 Angioedemas, Hereditary studies recruiting now, 9 (69%) set no upper age limit and 4 (31%) stop at 75 or younger; 7 take children under 18; 1 takes healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing icatibant in Angioedemas, Hereditary as a file.
02

Study summary

This is a phase IV clinical study. The investigators collect patients with a diagnosis of bradykinin induced angioedema. For a specific study period and prospectively arrange, the eligible patients who has an acute attack of angioedema could be treated by icatibant Injection (Icanticure®).

The drug, icatibant injection has been reimbursed by National Health Insurance Agency, Taiwan (NHI) in the treatment of diagnosed patients with hereditary angioedema. However, the reimbursement is still limited for some patients with atypical conditions. Therefore, Nang Kuang Company initiates a phase IV case collection study and supplies Icanticure® for free during the study period. Patients who still unable to obtain NHI's reimbursed icatibant drug is eligible for the inclusion, enter into the study and can be treated by Icanticure® to meet their clinical urgent needs. The safety and efficacy of Icanticure® are evaluated by the prospective, planed assessments in the enrolled patients.

03

Conditions studied

  • Bradykinin-mediated Angioedema
  • Hereditary Angioedema (HAE)
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The male or female patient is ≥20 years old at the time of .
  2. The informed consent form has been read, signed and dated by the patient.
  3. At the screening visit, the investigator diagnosed bradykinin-induced angioedema based on at least one of the following:

    • Recurrent attacks of edema and/or poor respond to antihistamines, or epinephrine
    • Recurrent angioedema attacks of abdominal, and/or laryngeal (inclusive of laryngeal and pharyngeal) areas
    • Angioedema without the presence of urticarial rashes
    • Known family history of angioedema
    • Known to have genetic defects related to hereditary angioedema
  4. Able to communicate well with the investigator, comply with study questionnaires, and other instruments used for collecting patient-reported outcomes.

Exclusion criteria

Exclusion Criteria:

  1. Known with a history of allergy or to the drug as judged by the investigator at the screening visit.
  2. The patient has a diagnosis of angioedema other than bradykinin induced angioedema.
  3. The patient has participated in another clinical study within the past 30 days before screening.
  4. Presence of liver disease or liver injury as indicated by an abnormal liver function profile such as (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), or total , if any one of them is out of the reference range.

    The definitions of out of the reference ranges are:

    • Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), or alkaline phosphatase (ALP) > 2.5 times (Upper Limit Normal);
    • Serum total bilirubin >= 1.5 times ULN;
  5. Presence of impaired renal function as indicated by abnormal creatinine or blood urea nitrogen values, if any one of them is out of the reference range.

    The definitions of out of the reference ranges are:

    • rate (\<= 40 mL/min) (estimated by Cockcroft-Gault formula) and serum creatinine >=1.5 times ULN;
    • Blood urea nitrogen value >= 1.5 times ULN
  6. Presence of impaired hematological or coagulation functions as indicated by abnormal measure values, if any one of them is out of the reference range.
  7. Evidence of symptomatic coronary artery disease based on medical history, in particular, unstable angina pectoris or severe coronary heart disease.
  8. Congestive heart failure ( Class 3 and 4).
  9. Stroke within the past 6 months.
  10. Known pregnancy and/or breast-feeding.
  11. In the opinion of the investigator: mental condition rendering the patient unable to understand the nature, scope and possible consequences of the study.
  12. In the opinion of the investigator: unlikely to comply with the protocol, for example, uncooperative attitude, inability to return for follow-up visits, or unlikely to complete the study for any reason.
  13. In the opinion of the investigator: inability to manage study medication or self-administration of an injection.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
5 participants (actual)

Study arms

  • Experimental
    Icatibant Injection (Icanticure®)

    Drug: Icatibant Injection (Icanticure®)

Interventions

  • 30 mg/3 ml injectable prefilled syringe for the treatment of acute attacks of hereditary angioedema (HAE) in children 2 years of age and older.

06

What researchers measure

Primary outcomes

  1. To evaluate the time to complete or near complete resolution from onset of symptoms

    The time of onset of acute attack, the time of Icanticure® given, the time of onset of symptom relief, and the time to complete relief of symptoms will be recorded by the patient in minutes. Time to complete relief of symptoms is defined as time from onset of symptoms to complete or near complete resolution as reported by the patient.

    Time frame: Time to complete or near complete resolution of symptoms as reported by the patient, an expected average of 8-10 hours

Secondary outcomes

  1. Percent Change in VAS pain score: VAS scale ranges from 0-10 with 0 being no any pain and 10 being the highest severity in pain

    The VAS pain scores from 0-10 will be recorded by patients themselves on the following timing, the time of onset of acute attack, the time of Icanticure® given, the time of onset of symptom relief, and the time to complete relief of symptom.

    Time frame: The time from the onset of acute attack to the time to complete or near complete resolution of symptoms as reported by the patient. The estimated period of time is considered to up to 24 hours.

  2. To evaluate volume change of edema from onset of symptoms to complete or near complete resolution.

    Volume change of edema will be recorded by patients themselves by using a tape to measure millimeters of the edema part on the following timing, the time of onset of acute attack, the time of Icanticure® given, the time of onset of symptom relief, and the time to complete relief of symptom.

    Time frame: Volume change will be measured from the onset of acute attack to the time to complete or near complete resolution of symptoms as reported by the patient. The estimated period of time is considered to up to 24 hours

  3. To evaluate the safety and tolerability: the safety profile of Icanticure® will be evaluated by the following parameters.

    1. Adverse events (AEs) incidence, but the adverse events are not included the pains related to angioedema symptoms which have been evaluated by the VAS pain scores. 2. Local injection site reaction

    Time frame: At least 24 hours post-dose of Icanticure®

07

Study locations

1 site
  • Taichung Veterans General Hospital
    Taichung, Taiwan
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2024 to primary completion in May 2025, 8 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2025
First posted
Dec 18, 2025
StartActual
Sep 27, 2024
Primary completionActual
May 27, 2025
CompletionActual
Sep 26, 2025
Last update
Dec 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07290855
Lead sponsor
Nang Kuang Pharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
Dec 18, 2025
Start date
Sep 27, 2024
Primary completion
May 27, 2025
Completion
Sep 26, 2025
Last update
Dec 18, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Icatibant

Start the discussion